Search Result

Pathways Recommended:	PROTAC Antibody-drug Conjugate/ADC Related

Results for "

PROTAC BRD4 Degrader linker conjugate

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Drug-Linker Conjugates for ADC (2) E3 Ligase Ligand-Linker Conjugates (13) PROTAC-Linker Conjugates for PAC (2) Target Protein Ligand-Linker Conjugates (4) ADC Payload (1) Apoptosis (2) Autophagy (1) Drug Derivative (1) Epigenetic Reader Domain (14) FLT3 (1) HIV (1) JAK (1) PROTACs (9)
By Research Areas:	Cancer (24) Infection (1)
Click Chemistry:	PROTAC Synthesis (3) Azide (3) Alkynes (1)

Inhibitors & Agonists

Click Chemistry

Targets Recommended: PROTAC-Linker Conjugates for PAC PROTAC Linkers ADC Linker Target Protein Ligand-Linker Conjugates Ligands for Target Protein for PROTAC Drug-Linker Conjugates for ADC E3 Ligase Ligand-Linker Conjugates

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-138632

**PROTAC BRD4 Degrader linker conjugate**	PROTACs Epigenetic Reader Domain PROTAC-Linker Conjugates for PAC	Cancer
PROTAC BRD4 Degrader linker conjugate is a linker-payload conjugate as well as a bifunctional degrader of *BRD4* that binds to VHL, consisting of *PROTAC* and a linker. PROTAC BRD4 Degrader linker conjugate can be conjugated with STEAP1 and CLL1 antibodies to degrade BRD4 protein, with DC₅₀ values of 0.86 nM and 7.6 nM, respectively. PROTAC BRD4 Degrader linker conjugate can be used in research related to prostate cancer and acute myeloid leukemia (BRD4 ligand: (HY-129939); VHL ligand: (HY-125845)) .\n

HY-133736

PROTAC BRD4 Degrader-5-CO-PEG3-N3	PROTAC-Linker Conjugates for PAC ADC Payload Epigenetic Reader Domain	Cancer
PROTAC BRD4 Degrader-5-CO-PEG3-N3 is a PROTAC-linker Conjugate for PAC, comprises the BRD4 degrader (MZ 1 (HY-107425) analog) and PEG-based linker. PROTAC BRD4 Degrader-5-CO-PEG3-N3 is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups. PROTAC BRD4 Degrader-5-CO-PEG3-N3 can be used for the research of HER2-positive breast cancer .

HY-131387

(S,R,S)-AHPC-Me-CO-CH2-PEG3-NH2	E3 Ligase Ligand-Linker Conjugates	Cancer
(S,R,S)-AHPC-Me-CO-CH2-PEG3-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the a VHL ligand and a linker. (S,R,S)-AHPC-Me-CO-CH2-PEG3-NH2 can be used in PROTAC BRD4 Degrader-5 (HY-133737) and PROTAC BRD4 Degrader-5-CO-PEG3-N3 (HY-133736) .

HY-138634

GNE-987 GSH linker-2	Drug-Linker Conjugates for ADC PROTACs Epigenetic Reader Domain	Cancer
GNE-987 GSH linker-2 is a drug-linker conjugates for ADC. GNE-987 GSH linker-2 is a conjugation of *PROTAC* GNE-987 (HY-129937A) and ADC linker GSH linker-2 (HY-182740), and can be used to prepare antibody-drug conjugates (ADC) for BRD4 degradation. GNE-987 GSH linker-2 can be used for the research of cancer .

HY-133139

Lenalidomide-PEG1-azide	E3 Ligase Ligand-Linker Conjugates	Cancer
Lenalidomide-PEG1-azide is a E3 ligase lgand-linker conjugate. Lenalidomide-PEG1-azide incorporates the Lenalidomide based cereblon ligand and a linker.?Lenalidomide-PEG1-azide?can be used to design a PROTAC BRD4 Degrader-2 (HY-133136) . Lenalidomide-PEG1-azide is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

HY-133138

Pomalidomide-PEG1-azide	E3 Ligase Ligand-Linker Conjugates	Cancer
Pomalidomide-PEG1-azide is an E3 ligase lgand-linker conjugate. Pomalidomide-PEG1-azide incorporates the Pomalidomide based cereblon ligand and a linker. Pomalidomide-PEG1-azide can be used to synthesis PROTAC BRD4 Degrader-1 (HY-133131) . PROTAC BRD4 Degrader-1 is a PROTAC connected by ligands for Cereblon and BRD4 with an IC₅₀ of 41.8 nM against BRD4 BD1. PROTAC BRD4 Degrader-1 can effectively degrade BRD4 protein and suppress c-Myc expression.

HY-164995

L1BC8	PROTACs Epigenetic Reader Domain Drug-Linker Conjugates for ADC	Cancer
L1BC8 (compound 13a) is a **BRD4 PROTAC** degrader with anticancer effects. L1BC8 is also a *drug-linker* conjugate for ADC** that can be used for the synthesis of ADCs. The resulting BRD4-degrader antibody conjugates exhibit potent and antigen-dependent BRD4 degradation and antiproliferation activities in cell-based experiments. (Pink: BRD4 ligand (HY-129939); Blue: VHL ligand (HY-125845); Black: linker (HY-171663)) .

HY-174996

NEP162	PROTACs Epigenetic Reader Domain Apoptosis	Cancer
NEP162 is a **BRD4 PROTAC** degrader with DC₅₀s of 1.2 and 1.6 μM in SW480 and U2OS cells. NEP162 exhibits antiproliferative activity, effectively inhibits tumor growth and induces apoptosis. NEP162 can be used for the study of osteosarcoma, colorectal cancer and non-small cell lung cancer, etc. (Pink: BRD4 ligand : (HY-78695), Blue: E3 ligase Ligand (HY-D2259), BLACK: Linker, E3 ligase ligand-linker conjugate (HY-174997)) .

HY-42429

CPI-203-PEG1-C3-O-COOH	Target Protein Ligand-Linker Conjugates Epigenetic Reader Domain	Cancer
CPI-203-PEG1-C3-O-COOH is a conjugate of the BRD4 ligand (HY-78695) and the linker (HY-42427). CPI-203-PEG1-C3-O-COOH can be used for synthesizing PROTAC BRD4 degrader ARV-771 (HY-100972) .

HY-176369

PROTAC BRD4 ligand-1-NH-PEG-phenol-PEG-COOtBu	Target Protein Ligand-Linker Conjugates Epigenetic Reader Domain	Cancer
PROTAC BRD4 ligand-1-NH-PEG-phenol-PEG-COOtBu is an Target Protein Ligand-Linker Conjugate that incorporates a ligand for *BRD4* and a PROTAC linker. PROTAC BRD4 ligand-1-NH-PEG-phenol-PEG-COOtBu can be used for synthesis of PROTAC BRD4 Degrader-14 (HY-138637) .

HY-175767

PROTAC BRD4 Degrader-39	PROTACs Epigenetic Reader Domain	Cancer
PROTAC BRD4 Degrader-39 is a selective targeting Bromodomain protein 4 (BRD4) degrader with an DC₅₀ value of 24.66 nM. PROTAC BRD4 Degrader-39 conjugates BRD PROTAC (ARV-771) (HY-100972) with carbohydrate. PROTAC BRD4 Degrader-39 selectively delivers to tumor cells with high GLUT1 expression, followed by GSH-triggered release of ARV-771 and degrades BRD4. PROTAC BRD4 Degrader-39 can inhibit tumor growth and show no significant toxicity. PROTAC BRD4 Degrader-39 can be used for the research of cancer, such as breast cancer . (Structure Note: Pink: BRD4 ligand (HY-78695); Blue: VHL ligand (HY-112078); Black: (HY-42427); BRD4 ligand-Linker: (HY-42429))

HY-130814

Thalidomide-NH-C4-NH2 TFA	E3 Ligase Ligand-Linker Conjugates Autophagy Apoptosis	Cancer
Thalidomide-NH-C4-NH2 TFA (compound 29c) is an E3 ligase ligand-linker conjugate, and incorporates the Thalidomide based cereblon ligand and a linker. Thalidomide-NH-C4-NH2 TFA is used in PROTAC BRD2/BRD4 degrader-1 (HY-130612). PROTAC BRD2/BRD4 degrader-1 is a potent and selective BET protein BRD4 and BRD2 degrader .

HY-175610

PROTAC FLT3/JAK2/BRD4 Degrader-1	PROTACs FLT3 JAK Epigenetic Reader Domain	Cancer
PROTAC FLT3/JAK2/BRD4 Degrader-1 is a PROTAC degrader that target FLT3, JAK2, and *BRD4* with DC₅₀ values of 5.23, 0.678, and 1.17 nM, respectively. PROTAC FLT3/JAK2/BRD4 Degrader-1 exhibits potent antiproliferative activity against MV4;11 cells (IC₅₀ = 0.79 nM) and FLT3 mutant-transformed Ba/F3 cells. PROTAC FLT3/JAK2/BRD4 Degrader-1 induces apoptosis in MV4;11 cells. PROTAC FLT3/JAK2/BRD4 Degrader-1 demonstrates significant anti-tumor efficacy in the MV4;11 xenograft model established in NOD SCID mice. PROTAC FLT3/JAK2/BRD4 Degrader-1 can be used for the study of acute myeloid leukemia (AML). (Pink: FLT3/JAK2/BRD4 ligand (HY-175611), Blue: CRBN Ligand (HY-W087383), Black: Linker, E3 ligase ligand-linker conjugate (HY-W897939)) .

HY-174813

Pomalidomide-PEG3-Cys	E3 Ligase Ligand-Linker Conjugates	Others
Pomalidomide-PEG3-Cys is an E3 ligase ligand-linker conjugate that incorporates a CRBN ligand Pomalidomide (HY-10984) and 3-unit PEG linker. Pomalidomide-PEG3-Cys can be used for synthesis of PROTAC BRD4 Degrader-33 (HY-174811) .

HY-W877997

Pomalidomide 5'-pip-acid	E3 Ligase Ligand-Linker Conjugates Drug Derivative	Cancer
Pomalidomide 5'-pip-acid is an E3 ligase ligand-linker conjugate derived from the molecular glue Pomalidomide (HY-10984), which can be used to synthesize the dual-target *PROTAC* degrader PROTAC CBP/p300/BRD4 Degrader-1 (HY-181758) targeting CBP/p300 and *BRD4. Pomalidomide 5'-pip-acid shows anti-proliferative activity against cancer cells with an IC₅₀* of 2.73 nM. Pomalidomide 5'-pip-acid induces anti-proliferative effects in cancer cells. Pomalidomide 5'-pip-acid is applicable to research related to prostate cancer and colorectal cancer .

HY-170808

PROTAC BRD4 Degrader-28	PROTACs Epigenetic Reader Domain	Cancer
PROTAC BRD4 Degrader-28 (Compound 4) is a PROTAC degrader targeting *BRD4. PROTAC* BRD4 Degrader-28 is promising for research of cancers (Pink: target protein ligand JQ-1 (carboxylic acid) (HY-78695); Black+ Blue: E3 ubiquitin ligase ligand-Linker conjugate Thalidomide-O-amido-C3-NH2 (HY-115560)) .

HY-173433

JV8	Epigenetic Reader Domain	Cancer
JV8 is a *BRD4* PROTAC degrader. JV8 promotes the ubiquitination and degradation of BRD4 and induces apoptosis. JV8 has antitumor activity in a mouse 4T1 orthotopic tumor model. (Pink: BRD4 ligand (HY-78695); Blue: E3 ligase VHL ligand (HY-173435); Black: Linker (HY-33366); E3 ligase VHL ligand-linker conjugate (HY-173436)) .

HY-176769

E3 Ligase Ligand-linker Conjugate 196	E3 Ligase Ligand-Linker Conjugates	Others
E3 Ligase Ligand-linker Conjugate 196 is an E3 ligase ligand-linker conjugate. E3 Ligase Ligand-linker Conjugate 196 can be used in the synthesis of PROTAC BRD4 Degrader-38 (HY-175240) .

HY-162875

PROTAC BRD4 Degrader-27	PROTACs Epigenetic Reader Domain	Cancer
PROTAC BRD4 Degrader-27 (compound 6b) is a PROTAC that selectively targets BRD4 (rather than BRD2/BRD3) and can also inhibit the expression of KLF5 transcription factor and exert anti-cancer activity. PROTAC *BRD4* Degrader-27 is composed of E3 ubiquitinase ligand Thalidomide-4-OH (HY-103596) (red part), PROTAC Linker γ-Aminobutyric acid (HY-N0067) (black part) and PROTAC target protein ligand PROTAC *BRD4* ligand-3 (HY-162876) (blue part), of which the active control of the target protein ligand is Mivebresib (HY-100015), and the conjugate of E3 ubiquitin ligase ligand + Linker is Pomalidomide 4'-alkylC3-acid (HY-131875) ^{[1] ^.}

HY-159777

JQ-1-PEG5-Alkyne	Target Protein Ligand-Linker Conjugates	Cancer
CPI-203-PEG5-Alkyne is a conjugate of target protein ligase and linker. CPI-203-PEG5-Alkyne can be used for synthesis of PROTAC BRD4-DCAF1 degrader-1 (HY-169151) .

HY-175241

T-01-C7-amide	E3 Ligase Ligand-Linker Conjugates	Others
T-01-C7-amide is an E3 ligase ligand-linker conjugate. T-01-C7-amide can be used in the synthesis of PROTAC BRD4 Degrader-36 (HY-175224) .

HY-174220

Boc-Dipiperidine-KLHDC2 ligand 1	E3 Ligase Ligand-Linker Conjugates	Cancer
Boc-Dipiperidine-KLHDC2 ligand 1 is an E3 ligase ligand-linker conjugate that incorporates a KLHDC2 ligand (HY-174218). Boc-Dipiperidine-KLHDC2 ligand 1 can be used for synthesis of PROTAC BRD4 Degrader-31 (HY-174210) .

HY-W957152

Deoxy-thalidomide-C4-NH2	E3 Ligase Ligand-Linker Conjugates	Cancer
Deoxy-thalidomide-C4-NH2 is a ligand-linker conjugate for the E3 ligase Cereblon (CRBN). Deoxy-thalidomide-C4-NH2 can be used in the synthesis of PROTAC BRD4 Degrader (HY-176449) .

HY-174997

PFI-7-O-C4-piperazin	E3 Ligase Ligand-Linker Conjugates	Cancer
PFI-7-O-C4-piperazin is a E3 ligase ligand-linker conjugate that can be used for synthesis of PROTACs, such as NEP162 (HY-174996). The E3 ligase ligand (PFI-7) of NEP162 is a highly selective antagonist of GID4 (K_D = 0.22 μM). NEP162 is a BRD4 PROTAC degrader with anti-tumor activity ^{[1] ^.}

HY-161652

Thalidomide-NH-C3-O-Ph(NO2)-methylester-O-pyrrolidine-2,5-dione	E3 Ligase Ligand-Linker Conjugates	Cancer
Thalidomide-NH-C3-O-Ph(NO2)-methylester-O-pyrrolidine-2,5-dione is the conjugate of a linker and a ligand for E3 ligase. Thalidomide-NH-C3-O-Ph(NO2)-methylester-O-pyrrolidine-2,5-dione can be used for synthesis of PROTAC BRD4 Degrader-26 (HY-161650) .

HY-181164

PROTAC BRD4 Degrader-43	PROTACs Epigenetic Reader Domain HIV	Infection
PROTAC BRD4 Degrader-43 is a **BRD4 PROTAC** degrader. PROTAC BRD4 Degrader-43 recruits the DCAF1-DDB1-Cul4A E3 ligase complex via a Vpr-derived peptide moiety to induce BRD4 ubiquitination and degradation through the ubiquitin-proteasome system. PROTAC BRD4 Degrader-43 exhibits potent HIV latency-reversing activity. PROTAC BRD4 Degrader-43 can be used for the research of HIV-1 latent infection . (Pink: BRD4 ligand (HY-13030); Blue: Cul4A-DDB1-DCAF1 ligand (HY-P11640); Black: conjugate of PEG linker + cell-penetrating peptide (HY-P2483))

HY-179589

JQ-1 (carboxylic acid)-amine-PEG8-cyanogen	Target Protein Ligand-Linker Conjugates Epigenetic Reader Domain	Cancer
JQ-1 (carboxylic acid)-amine-PEG8-cyanogen is a Target Protein Ligand-Linker Conjugate that incorporates a ligand for BRD4 (HY-78695) and a PROTAC linker, which recruits E3 ligases. JQ-1 (carboxylic acid)-amine-PEG8-cyanogen can be used for the synthesis of PROTAC BET Degrader-14 (HY-179588 ) .

HY-181868

Lenalidomide-CO-C7-NH2	E3 Ligase Ligand-Linker Conjugates	Cancer
Lenalidomide-CO-C7-NH2 is a CRBN-dependent intermediate of BET PROTAC degrader. Consisting of the E3 ubiquitin ligase ligand Lenalidomide (HY-A0003) conjugated with a **PROTAC linker*, Lenalidomide-CO-C7-NH2 induces the protein degradation. By depleting BRD4, PROTAC* BET Degrader-16 effectively inhibits cancer cell proliferation, induces cell cycle arrest and promotes apoptosis, thereby exhibiting significant anti-tumor activity in xenograft models. Lenalidomide-CO-C7-NH2 serves as an important tool molecule for the study of acute myeloid leukemia .

Cat. No.	Product Name		Classification

HY-133736

PROTAC BRD4 Degrader-5-CO-PEG3-N3		Azide PROTAC Synthesis
PROTAC BRD4 Degrader-5-CO-PEG3-N3 is a PROTAC-linker Conjugate for PAC, comprises the BRD4 degrader (MZ 1 (HY-107425) analog) and PEG-based linker. PROTAC BRD4 Degrader-5-CO-PEG3-N3 is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups. PROTAC BRD4 Degrader-5-CO-PEG3-N3 can be used for the research of HER2-positive breast cancer .

HY-133139

Lenalidomide-PEG1-azide		Azide PROTAC Synthesis
Lenalidomide-PEG1-azide is a E3 ligase lgand-linker conjugate. Lenalidomide-PEG1-azide incorporates the Lenalidomide based cereblon ligand and a linker.?Lenalidomide-PEG1-azide?can be used to design a PROTAC BRD4 Degrader-2 (HY-133136) . Lenalidomide-PEG1-azide is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

HY-133138

Pomalidomide-PEG1-azide		PROTAC Synthesis Azide
Pomalidomide-PEG1-azide is an E3 ligase lgand-linker conjugate. Pomalidomide-PEG1-azide incorporates the Pomalidomide based cereblon ligand and a linker. Pomalidomide-PEG1-azide can be used to synthesis PROTAC BRD4 Degrader-1 (HY-133131) . PROTAC BRD4 Degrader-1 is a PROTAC connected by ligands for Cereblon and BRD4 with an IC₅₀ of 41.8 nM against BRD4 BD1. PROTAC BRD4 Degrader-1 can effectively degrade BRD4 protein and suppress c-Myc expression.

HY-159777

JQ-1-PEG5-Alkyne		Alkynes
CPI-203-PEG5-Alkyne is a conjugate of target protein ligase and linker. CPI-203-PEG5-Alkyne can be used for synthesis of PROTAC BRD4-DCAF1 degrader-1 (HY-169151) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.